BOSTON, Nov. 07, 2025 — Leads & Copy — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, has announced its participation in two upcoming investor conferences.
The company will engage in a fireside chat at the TD Cowen Virtual Immunology & Inflammation Summit on Wednesday, November 12, 2025, at 2:30 p.m. ET. Following this, Vor Bio will participate in the 8th Annual Evercore Healthcare Conference with a fireside chat scheduled for Tuesday, December 2, 2025, at 3:00 p.m. ET in Miami, FL.
Live webcasts and archived replays of the fireside chats will be accessible through the investors section of Vor Bio’s website.
Vor Bio aims to advance telitacicept, a dual-target fusion protein, through Phase 3 clinical development and potential commercialization for autoantibody-driven conditions.
Carl Mauch can be reached at cmauch@vorbio.com, and Sarah Spencer can be reached at investors@vorbio.com.
Source: Vor Bio
